Literature DB >> 9380798

NSAID-induced apoptosis in Rous sarcoma virus-transformed chicken embryo fibroblasts is dependent on v-src and c-myc and is inhibited by bcl-2.

X Lu1, D W Fairbairn, W S Bradshaw, K L O'Neill, D L Ewert, D L Simmons.   

Abstract

Mounting epidemiological and experimental evidence implicates non-steroidal antiinflammatory drugs as anti-tumorigenic agents. Our previous work showed that nonsteroidal antiinflammatory drug treatment of src-transformed chicken embryo fibroblasts caused apoptosis--a mechanism by which these drugs might exert their anti-tumorigenic effect. The present studies employ a sensitive technique for detecting single- and double-stranded DNA cleavage (the comet assay) to quantitate apoptosis. By this method pp60v-src, which antagonizes apoptosis in many cell systems, was found to induce apoptosis in 11-23% of serum-starved fibroblasts. However, treatment with diclofenac following pp60v-src activation produced a much stronger response beginning within 6 hours of treatment that resulted in 100% lethality. During cell death, cyclooxygenase-2 but not cyclooxygenase-1 mRNA was found to be uniformly increased by all apoptotic drugs tested. Examination of the expression of apoptosis-associated genes showed that c-rel and p53 (found in normal or v-src-transformed chicken embryo fibroblasts at moderate levels), and bcl-2 (present at an extremely low level) were largely unchanged by treatment with eight different nonsteroidal antiinflammatory drugs. However, overexpression of human bcl-2 inhibited diclofenac-mediated apoptosis by 90%, demonstrating directly that bcl-2 expression can regulate nonsteroidal antiinflammatory drug induction of cell death. The proto-oncogene c-myc is known to cause apoptosis in chicken embryo fibroblasts when artificially overexpressed in cells deprived of trophic factors. We found that nonsteroidal antiinflammatory drug treatment following pp60v-src activation persistently induced myc protein and mRNA by more than 20-fold above that evoked by pp60v-src activation alone. Moreover, transfection of antisense c-myc oligonucleotides reduced drug-induced myc expression by 80% and caused a concomitant 50% reduction in cell death. These findings suggest that nonsteroidal antiinflammatory drug-induced apoptosis proceeds through a src/myc dependent pathway which is negatively regulated by bcl-2.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9380798     DOI: 10.1016/s0090-6980(97)00125-1

Source DB:  PubMed          Journal:  Prostaglandins        ISSN: 0090-6980


  6 in total

1.  Induction of an acetaminophen-sensitive cyclooxygenase with reduced sensitivity to nonsteroid antiinflammatory drugs.

Authors:  D L Simmons; R M Botting; P M Robertson; M L Madsen; J R Vane
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-16       Impact factor: 11.205

2.  v-Src generates a p53-independent apoptotic signal.

Authors:  B L Webb; E Jimenez; G S Martin
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

3.  Induction but not inhibition of COX-2 confers human lung cancer cell apoptosis by celecoxib.

Authors:  Robert Ramer; Udo Walther; Philipp Borchert; Stefan Laufer; Michael Linnebacher; Burkhard Hinz
Journal:  J Lipid Res       Date:  2013-08-12       Impact factor: 5.922

4.  Cyclooxygenase (COX)-2 and granulosa cell apoptosis in vitro.

Authors:  Angela S Caffrey; William C Patton; Johannah U Corselli; Ron E Swensen; Alan King; Philip J Chan
Journal:  J Assist Reprod Genet       Date:  2002-12       Impact factor: 3.412

5.  The role of cyclooxygenase inhibition in the antineoplastic effects of nonsteroidal antiinflammatory drugs (NSAIDs).

Authors:  S J Shiff; B Rigas
Journal:  J Exp Med       Date:  1999-08-16       Impact factor: 14.307

Review 6.  Hitting the Bull's-Eye in Metastatic Cancers-NSAIDs Elevate ROS in Mitochondria, Inducing Malignant Cell Death.

Authors:  Stephen John Ralph; Rhys Pritchard; Sara Rodríguez-Enríquez; Rafael Moreno-Sánchez; Raymond Keith Ralph
Journal:  Pharmaceuticals (Basel)       Date:  2015-02-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.